TTR and Familial transthyretin-related amyloidosis: Moreover, CRISPR/Cas technology has recently obtained a considerable milestone in in vivo gene editing to treat transthyretin amyloidosis, achieving the first direct body bloodstream deployment of lipid nanoparticles encapsulating CRISPR/Cas9 mRNA (i.e., Cas9 and gRNA) to safely decline the synthesis of the TTR protein associated with the disease by an average of 87%, whereas conventional methods report up to a 80% TTR synthesis decline [175,176,177].